QQ客服 官方微博 反馈留言

	Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
	Song, Yuqin; Zhou, Keshu; Zou, Dehui; Zhou, Jianfeng; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie
	2018
卷号	132
ISSN号	0006-4971
DOI	10.1182/blood-201/1-99-117956
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6349059
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Song, Yuqin,Zhou, Keshu,Zou, Dehui,et al. Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial[J],2018,132.
APA	Song, Yuqin.,Zhou, Keshu.,Zou, Dehui.,Zhou, Jianfeng.,Hu, Jianda.,...&Zhu, Jun.(2018).Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial.,132.
MLA	Song, Yuqin,et al."Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial".132(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。